Matthew Frederick LeFebvre, Roseville, MN (US); Yasuko Hatta, Madison, WI (US); Pamuk Bilsel, Madison, WI (US); and Michael J. Moser, Madison, WI (US)
Assigned to FluGen, Inc., Madison, WI (US)
Filed by FluGen, Inc., Madison, WI (US)
Filed on Feb. 18, 2022, as Appl. No. 17/675,297.
Application 17/675,297 is a continuation of application No. 16/676,119, filed on Nov. 6, 2019, granted, now 11,253,584.
Application 16/676,119 is a continuation of application No. 15/681,613, filed on Aug. 21, 2017, granted, now 10,500,267, issued on Dec. 10, 2019.
Application 15/681,613 is a continuation of application No. 15/125,763, granted, now 9,757,446, issued on Sep. 12, 2017, previously published as PCT/US2015/020580, filed on Mar. 13, 2015.
Claims priority of provisional application 61/954,346, filed on Mar. 17, 2014.
Prior Publication US 2023/0029543 A1, Feb. 2, 2023
1. An immunogenic composition comprising the nucleic acid sequence of SEQ ID NO:35, wherein SEQ ID NO:35 further comprises a nucleic acid sequence encoding one or more antigens.